Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.

You may also be interested in...



AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine

Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.

AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine

Company moving into sickle cell disease in all-stock acquisition of privately held SynthRx.

Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure

Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS065381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By